In the last decade, many publications have explored resistance mechanisms to TMZ, including the tumor heterogeneity, MGMT (O-6-methylguanine-DNA methyltransferase), and mismatch repair status, but these processes have not completely explained this lack of sensitivity in pediatric patients. This evidence concerns the gene MGMT and neoplasm.